Request To Download Free Sample of This Strategic Report@ COPD and asthma devices are crucial in the management and treatment of respiratory diseases, providing relief and improving the quality of ...

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a ...

GlaxoSmithKline (GSK)’s B7-H3-targeted antibody-drug conjugate (ADC), GSK’227 has gained priority medicines (PRIME) ...

Dr. Gur Levy, Respiratory Medical Expert at GSK, said, "We have been pioneering efforts for decades to develop new ...

But enrollment for all clinical studies of infant RSV vaccines is now on hold due to safety concerns, explained a Dec. 11 ...

The news followed an investigation by POLITICO's E&E News into climate-friendly inhalers and how drug giants are developing ...

The revenue for GSK-3810109 is expected to reach an annual total of $132 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to ...

Following news of RSV lower respiratory tract infections in infants immunized with Moderna’s investigational RNA vaccines, ...

Researchers identified optimal assessment tools for RSV, influenza, and hMPV that accurately supplement the identification of ...

Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...

Background With higher valency pneumococcal vaccines on the horizon and new adult immunisation strategies under discussion, ...